Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
10:20am, Friday, 15'th Jul 2022 Zacks Investment Research
Sector ETF report for FBT
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
04:01pm, Thursday, 14'th Jul 2022
Conference Call and Webcast Scheduled for Thursday, August 4 SAN DIEGO , July 14, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
10:20am, Thursday, 07'th Jul 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
04:01pm, Wednesday, 08'th Jun 2022
SAN DIEGO , June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
10:20am, Friday, 06'th May 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Neurocrine Biosciences (NBIX) Q1 2022 Earnings Call Transcript
08:30am, Thursday, 05'th May 2022 The Motley Fool
NBIX earnings call for the period ending March 31, 2022.
Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates
12:45pm, Wednesday, 04'th May 2022 Zacks Investment Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2022 Results - Earnings Call Transcript
12:30pm, Wednesday, 04'th May 2022
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO & Director Matthew Abernethy - CFO Eric
Neurocrine Biosciences (NBIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:50pm, Wednesday, 27'th Apr 2022
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
04:01pm, Wednesday, 13'th Apr 2022
Conference Call and Webcast Scheduled for Wednesday, May 4 SAN DIEGO , April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarte
What 8 Analyst Ratings Have To Say About Neurocrine Biosciences
02:06pm, Monday, 04'th Apr 2022 Benzinga
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
5
0
0
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patien
